Abstract
Control of virus-induced airway inflammation in patients with chronic bronchopulmonary disorders remains an urgent medical task. Managing the immune response in acute respiratory viral infections (ARVIs) in these patients is a promising area. This review summarizes the results of observational programs and initiative studies on the experience with a drug based on technologically processed antibodies in pulmonary practice. This drug is characterized by immune-mediated antiviral and antibacterial effects. The mechanism of its action implies the activation of antigen processing and presentation involving major histocompatibility complex molecules, which in turn contributes to an adequate immune response in the infectious process. Therefore, this drug can be used for treating ARVIs in patients with a high risk of unfavorable course of respiratory infections. Our findings demonstrate that this drug prevents the exacerbation of chronic bronchopulmonary disorders in ARVIs. Its inclusion in complex therapy for community-acquired pneumonia in patients with a higher risk of having resistant flora provided the completion of the treatment course without changing the antibiotic. KEYWORDS: chronic bronchopulmonary disorders, chronic obstructive pulmonary disease (COPD), asthma, chronic bronchitis, community- acquired pneumonia, antibiotic resistance. FOR CITATION: Prozorova G.G., Zaytsev A.A., Petrov V.A. Prevention of exacerbations of chronic respiratory diseases. Russian Medical Inquiry. 2023;7(8):524–528 (in Russ.). DOI: 10.32364/2587-6821-2023-7-8-8.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
